Table 1.
Characteristics of 304 patients receiving 360 treatments [chemotherapeutic treatment, hematopoietic stem cells transplantation (HSCT), or experimental chemotherapeutic treatment] in one of the study centers.
| Centers | Frankfurt | Münster | Vienna | Total |
|---|---|---|---|---|
| Number of patients | 107 | 81 | 116 | 304 |
| Male/female | 71/36 | 52/29 | 67/49 | 190/114 |
| Age (median, range in years) | 5.9 (0.2–17.8) | 6.5 (0.1–17.9) | 6.5 (0.1–17.9) | 6.0 (0.1–17.9) |
| Total number of treatments | 127∗ | 98∗ | 135∗ | 360∗ |
| BFM-based chemotherapeutic treatments ∗∗ | 59 | 59 | 93 | 211 |
| Number of chemotherapy cycles (total) | 198 | 192 | 371 | 761 |
| Average number (range) of chemotherapy cycles per patient | 3.4 (2–8) | 3.2 (1–8) | 4.0 (2–8) | 3.8 (1–8) |
| Underlying malignancy (patients with BFM-based chemotherapy) | ||||
| ALL (total) | 40 | 33 | 60 | 133 |
| ALL-SR | 16 | 15 | 21 | 52 |
| ALL-MR | 17 | 11 | 22 | 50 |
| ALL-HR | 7 | 7 | 17 | 31 |
| ALL relapse | 3 | 3 | 12 | 18 |
| AML | 6 | 9 | 8 | 23 |
| AML relapse | 0 | 3 | 2 | 5 |
| NHL | 10 | 11 | 11 | 32 |
| Experimental chemotherapeutic treatments∗∗ | 8 | 2 | 1 | 11 |
| Hematopoietic stem cell transplantation | 60 | 37 | 41 | 138 |
| Underlying disease | ||||
| ALL/ALL relapse | 23 | 14 | 15 | 52 |
| AML/AML relapse | 10 | 8 | 8 | 26 |
| MDS/AA | 8 | 8 | 8 | 24 |
| Lymphoma | 4 | 4 | 4 | 12 |
| Immunodeficiency | 9 | 1 | 4 | 14 |
| Sickle cell disease | 2 | 0 | 0 | 2 |
| Thalassemia | 1 | 0 | 1 | 2 |
| Other∗∗∗ | 3 | 2 | 1 | 6 |
∗ A total of 34, 8, and 2 patients, respectively, received more than one treatment and were included twice, three times or four times in the study. ∗∗Chemotherapeutic treatments were divided in treatment regimens based on current Berlin-Frankfurt-Münster (BFM) trials and in treatment regimens with experimental character in the pediatric setting such as blinatumomab or bortezomib (“experimental chemotherapeutic treatment”). Experimental chemotherapeutic treatment was excluded from further analysis. ∗∗∗Includes two patients each with rhabdomyosarcoma and hemophagocytic syndrome, and one patient each with Blackfan-Diamond anemia and chronic myeloid lymphoma. ALL, acute lymphoblastic leukemia; ALL-SR, ALL-standard-risk; ALL-MR, ALL-medium-risk; ALL-HR, ALL-high-risk; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; AA, aplastic anemia.